Latest Healthcare News

EBOS Group Limited has updated its final dividend details for the six months ending June 2025, confirming a fully franked ordinary dividend and specifying the Dividend Reinvestment Plan strike price.

CloudHolter Pty Ltd reported a substantial $39.7 million net loss for FY2025 amid ongoing cash outflows but continues to raise capital through convertible notes as it targets an IPO by year-end.

Epsilon Healthcare’s manufacturing arm has secured updated GMP certificates covering domestic and EU/UK markets, reinforcing its quality credentials and paving the way for expanded international contract manufacturing.

EMVision Medical Devices has raised $12 million through a placement backed by institutional investors, including strategic partner Keysight Technologies, and launched a Share Purchase Plan to raise up to $2 million from existing shareholders. The capital will support key clinical and regulatory milestones for its neurodiagnostic devices over the next two years.

EBR Systems has achieved a significant commercial milestone with its tenth US implant of the WiSE wireless cardiac pacing system, setting the stage for broader market adoption supported by new reimbursement schemes.

PainChek’s UK pilot reveals significant clinical improvements and economic benefits, positioning the digital pain assessment app for broader adoption in Scotland and beyond.

Visionflex Group’s cornerstone investors are converting $3.25 million of debt into equity at double the last closing price, paving the way for a debt-free balance sheet and a streamlined capital structure.

Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.

Regis Healthcare acknowledges the Australian Government’s recent announcement to increase aged care funding through higher AN-ACC prices and hotelling supplements, aimed at supporting wage rises for care workers. The company is currently assessing the financial implications of these changes.

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.